EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Molecular Profile of Hormone‐Sensitive Prostate Cancer Defines High Risk Patients

Claudia Piombino iD, Cecilia Nasso, Stefania Bettelli, Samantha Manfredini, Maria Giuseppa Vitale, Stefania Pipitone, Cinzia Baldessari, Matteo Costantini, Albino Eccher, Ilenia Mastrolia, Virginia Catani iD, Francesca Bacchelli und 3 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Claudia Piombino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, European Union, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The therapeutic management of metastatic hormone‐sensitive prostate cancer (mHSPC) is still based on clinical and pathological parameters due to the lack of biomarkers that may drive tailored treatment.

Methods

In this non‐randomized, single‐center, retrospective trial, we searched for a genetic signature using the NanoString nCounter PanCancer Pathways Panel on formalin‐fixed paraffin embedded prostate cancer samples belonging to 48 patients with de novo or relapsed mHSPC. Patients were divided into a high‐clinical‐risk group ( n = 36) and a low‐clinical‐risk group ( n = 12) according to the mean time to metastatic relapse.

Results

The analysis of Nanostring nCounter Panel data revealed differential expression of 42 genes between high‐clinical‐risk and low‐clinical‐risk groups. All the genes except for NR4A1 and FOS were upregulated in the high‐clinical‐risk group. A general overexpression of apoptosis, PI3K and MAPK pathway‐related genes, including AKT2, was observed in the high‐clinical‐risk group.

Conclusion

The differential genetic signature identified between the two study groups revealed novel biomarkers in mHSPC, additionally suggesting new therapeutic targets within the hormone sensitive phase, such as AKT2 . Further prospective larger cohort studies are needed to assess the prognostic value of our findings and their exact role in prostate cancer progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorHumansMaleAgedRetrospective StudiesMiddle AgedGene Expression Regulation, NeoplasticGene Expression ProfilingPrognosisTranscriptome

Stichwörter der Autor:innen

AKT2FOSNR4A1NanoString nCounter PanCancer Pathways Panelmetastatic hormone‐sensitive prostate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  • Division of Oncology, S. Corona Hospital, Pietra Ligure, Italy.
  • Division of Molecular Pathology and Predictive Medicine, University Hospital of Modena, Modena, Italy.
  • Department of Pathology, University Hospital of Modena, Modena, Italy.
  • Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy.
  • Clinical Trials Office, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy.

ORCID-Profile: Claudia Piombino, Virginia Catani

Förderung

  • Ministero dell'Università e della Ricerca
  • European Union
  • European Commission

Zitieren

APA

Piombino, C., Nasso, C., Bettelli, S., Manfredini, S., Vitale, M. G., Pipitone, S., Baldessari, C., Costantini, M., Eccher, A., Mastrolia, I., Catani, V., Bacchelli, F., Ferretti, S., Dominici, M., & Sabbatini, R. (2025). A Novel Molecular Profile of Hormone‐Sensitive Prostate Cancer Defines High Risk Patients. Cancer Medicine. https://doi.org/10.1002/cam4.70472

Vancouver

Piombino C, Nasso C, Bettelli S, Manfredini S, Vitale MG, Pipitone S, et al. A Novel Molecular Profile of Hormone‐Sensitive Prostate Cancer Defines High Risk Patients. Cancer Medicine. 2025. doi:10.1002/cam4.70472

BibTeX
@article{Piombino2025,
  author = {Piombino, Claudia and Nasso, Cecilia and Bettelli, Stefania and Manfredini, Samantha and Vitale, Maria Giuseppa and Pipitone, Stefania and Baldessari, Cinzia and Costantini, Matteo and Eccher, Albino and Mastrolia, Ilenia and Catani, Virginia and Bacchelli, Francesca and Ferretti, Stefania and Dominici, Massimo and Sabbatini, Roberto},
  title = {A Novel Molecular Profile of Hormone‐Sensitive Prostate Cancer Defines High Risk Patients},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70472}
}
Kostenlos starten →